Search

Displaying results 7611 - 7620 of 10000 in total
  1. Drug

    Forigerimod

    go.drugbank.com/drugs/DB12490
    Investigational

    Forigerimod is under investigation for the treatment of Lupus Erythematosus, Systemic.

  2. Drug

    PF-00446687

    go.drugbank.com/drugs/DB12517
    Investigational

    PF-00446687 has been investigated for the treatment of Erectile Dysfunction.

  3. Drug

    Combretastatin

    go.drugbank.com/drugs/DB12596
    Investigational

    Combretastatin has been investigated for the treatment of Anaplastic Thyroid Cancer.

  4. Drug

    Intetumumab

    go.drugbank.com/drugs/DB12701
    Investigational

    Intetumumab has been used in trials studying the treatment of Melanoma.

  5. Drug

    beta-Apopicropodophyllin

    go.drugbank.com/drugs/DB15590
    Experimental

    beta-Apopicropodophyllin is a component of the freshwater plant _Micranthemum umbrosum_.

  6. Drug

    N-Ethylretinamide

    go.drugbank.com/drugs/DB03917
    Experimental

    N-Ethylretinamide is the ethylamide of all-trans B-retinoic acid.

  7. Drug

    MVA-BN-brachyury-TRICOM vaccine

    go.drugbank.com/drugs/DB17424
    Investigational

    of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3. … [L44513] MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)‐Brachyury booster vaccine.

  8. Drug

    Inactivated SARS-Cov-2 Vaccine

    go.drugbank.com/drugs/DB15862
    Investigational

    Developed by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 strain of SARS-CoV-2. … [A220158] Results from these trials showed low rates of adverse reactions and demonstrated immunogenicity.

  9. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    [A259063] It was formerly investigated for the treatment of beta-thalassemia, and it is currently being investigated for the treatment of sickle cell disease.[L46148] … It consists of autologous CD34+ hematopoietic stem precursor cells (HSPC) modified ex vivo by zinc finger nucleases (ZFN) that target the BCL11A gene erythroid-specific enhancer (ESE) to increase endogenous

  10. Drug

    Flizasertib

    go.drugbank.com/drugs/DB21613
    Investigational

    Flizasertib has a monoisotopic molecular weight of 271.11 Da. … The usage of the INN stem '-sertib' in the name indicates that Flizasertib is a serine/threonine kinase inhibitor.